Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022
By Aridis Pharmaceuticals, Inc.
Published - Nov 21, 2022, 06:33 PM ET
Last Updated - Apr 26, 2024, 09:39 AM EDT
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP
expected in December of this year
LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022.
Third Quarter Highlights
